Seer (SEER) Q4 2025 earnings review
Growth Hits a Wall, But Cash Runway Remains Massive
Seer is a story of two opposing realities. On the operations side, management successfully cut costs, slashed the net loss by 26% YoY, and expanded the instrument installed base by an impressive 67%. But on the top line, the growth narrative has completely stalled. Crippled by NIH funding uncertainty and severe macroeconomic budget constraints, revenue growth decelerated from 37% in Q1 to a mere 5% in Q4. More alarmingly, the FY26 guidance implies a dismal 3% growth rate, casting serious doubt on when, or if, the growing installed base and heavily-touted Thermo Fisher partnership will translate into meaningful consumable pull-through.
🐂 Bull Case
Seer ended the year with $240.6M in cash and investments. With net losses shrinking sequentially every quarter and an annual cash burn of roughly $60M, the company has an estimated 4-year runway to outlast the current life sciences spending freeze without diluting shareholders.
The company placed 33 instruments in 2025, expanding its installed base by 67% to 82 units. Once academic budgets unlock, this base is primed for high-margin consumable pull-through.
🐻 Bear Case
The FY26 revenue guidance of $16-18M implies practically zero growth. If Seer cannot monetize its newly placed instruments via consumables, the platform's recurring revenue model is broken.
With roughly 30% of historical revenue tied to government and academic customers, Seer is uniquely vulnerable to NIH funding pauses and political budget battles, which are currently paralyzing capital expenditures.
⚖️ Verdict: 🔴
Bearish. Disciplined cost controls and a fortress balance sheet keep the lights on, but a life sciences tools company guiding for 3% annual growth is in the penalty box until macro spending thaws and consumable revenues prove they can scale.
Key Themes
Severe Deceleration in Revenue Growth
Seer's revenue trajectory is decelerating at an alarming pace. Year-over-year growth went from 37% in 25Q1, to 32% in 25Q2, collapsed to 2% in 25Q3, and limped to 5% in 25Q4. The persistent gap between successful instrument placements (up 67%) and recognized revenue indicates severe delays in consumable utilization and elongated sales cycles.
Relentless Operational Cost Reductions
Management executed a masterful cost-control strategy in 2025. Q4 Operating Expenses fell 23% YoY to $19.6M, driven by major reductions in lab expenses, professional services, and stock-based compensation (which fell from $6.0M to $3.2M YoY in Q4). This discipline allowed gross margins to tick up to 52%.
The Academic and NIH Funding Freeze
The macroeconomic picture is punishing Seer's core customer base. Management explicitly cited 'ongoing budgetary pressures, including uncertainty around NIH funding in the fourth quarter' as the primary headwind. Until these government pipelines unclog, academic institutions are hoarding cash rather than running high-volume Proteograph consumable assays.
STAC and SIPP Programs Driving Instrument Placements
The Seer Technology Access Center (STAC) and Strategic Instrument Placement Program (SIPP) remain the critical engines for growth. By allowing capital-constrained customers to adopt the technology without massive upfront CapEx, Seer managed to place 33 instruments in 2025 despite the harsh macro environment. Q4 service revenue, largely STAC-driven, held steady at $1.2M.
Thermo Fisher Partnership Fails to Move the Needle (Yet)
Despite previous quarters highlighting the Thermo Fisher co-marketing agreement as a major commercial catalyst, its financial impact remains invisible in the numbers. The 2026 revenue guidance implies that this partnership will not generate material commercial acceleration in the near term.
Other KPIs
Accelerating slightly on a YoY basis (+20% vs $2.35M in 24Q4). This highlights that core hardware and consumable demand is still expanding, whereas the total revenue figure was dragged down by the complete evaporation of related-party revenues which existed in late 2024.
Decreased from ~$300M at the end of 2024. The company burned roughly $60M across the year, a highly sustainable rate given the current capitalization. Seer remains one of the best-capitalized small-cap life science tool companies in the market.
Guidance
Decelerating. The midpoint of $17.0M implies a meager 2.5% YoY growth rate over 2025's $16.6M. This indicates that management expects zero macro recovery in 2026, assuming elongated sales cycles and depressed consumable pull-through will persist for another 12 months.
Key Questions
Thermo Fisher Disconnect
Given the completion of sales force training for the Thermo Fisher partnership in early 2025, why does the 2026 guidance imply essentially flat revenue growth? Is the partnership yielding smaller deal sizes or just taking longer to close?
Consumable Pull-Through Rates
With the installed base growing 67% to 82 instruments, what is the current annualized consumable pull-through per active instrument, and how much of that is currently suppressed by academic budget freezes?
Path to Breakeven Timeline
You have done an excellent job managing cash burn down to $16M this quarter. If revenue remains stuck in the $16-20M range for the next two years, are there further operational levers to pull to reach cash flow breakeven, or does the model require a macro recovery?